These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34460809)

  • 1. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.
    Cassidy T; Nichol D; Robertson-Tessi M; Craig M; Anderson ARA
    PLoS Comput Biol; 2021 Aug; 17(8):e1009348. PubMed ID: 34460809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Gerlinger M; Swanton C
    Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding the role of phenotypic switching in cancer drug resistance.
    Gunnarsson EB; De S; Leder K; Foo J
    J Theor Biol; 2020 Apr; 490():110162. PubMed ID: 31953135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stochastic modeling of phenotypic switching and chemoresistance in cancer cell populations.
    Kumar N; Cramer GM; Dahaj SAZ; Sundaram B; Celli JP; Kulkarni RV
    Sci Rep; 2019 Jul; 9(1):10845. PubMed ID: 31350465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour heterogeneity and the evolution of polyclonal drug resistance.
    Burrell RA; Swanton C
    Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An elementary approach to modeling drug resistance in cancer.
    Tomasetti C; Levy D
    Math Biosci Eng; 2010 Oct; 7(4):905-18. PubMed ID: 21077714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conceptualizing a tool to optimize therapy based on dynamic heterogeneity.
    Liao D; Estévez-Salmerón L; Tlsty TD
    Phys Biol; 2012 Dec; 9(6):065005. PubMed ID: 23197078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drivers of dynamic intratumor heterogeneity and phenotypic plasticity.
    Biswas A; De S
    Am J Physiol Cell Physiol; 2021 May; 320(5):C750-C760. PubMed ID: 33657326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.
    Lorenzi T; Chisholm RH; Clairambault J
    Biol Direct; 2016 Aug; 11(1):43. PubMed ID: 27550042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
    Nijman SMB
    Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The great escape: tumour cell plasticity in resistance to targeted therapy.
    Boumahdi S; de Sauvage FJ
    Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.
    Murtaza M; Dawson SJ; Tsui DW; Gale D; Forshew T; Piskorz AM; Parkinson C; Chin SF; Kingsbury Z; Wong AS; Marass F; Humphray S; Hadfield J; Bentley D; Chin TM; Brenton JD; Caldas C; Rosenfeld N
    Nature; 2013 May; 497(7447):108-12. PubMed ID: 23563269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisation.
    Chisholm RH; Lorenzi T; Clairambault J
    Biochim Biophys Acta; 2016 Nov; 1860(11 Pt B):2627-45. PubMed ID: 27339473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolution of resistance to anti-cancer therapy during general dosing schedules.
    Foo J; Michor F
    J Theor Biol; 2010 Mar; 263(2):179-88. PubMed ID: 20004211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosage strategies for delaying resistance emergence in heterogeneous tumors.
    Vakil V; Trappe W
    FEBS Open Bio; 2021 May; 11(5):1322-1331. PubMed ID: 33638275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stochastic modeling of drug resistance in cancer.
    Komarova N
    J Theor Biol; 2006 Apr; 239(3):351-66. PubMed ID: 16194548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of resistance to targeted anti-cancer therapies during continuous and pulsed administration strategies.
    Foo J; Michor F
    PLoS Comput Biol; 2009 Nov; 5(11):e1000557. PubMed ID: 19893626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
    Wooten DJ; Quaranta V
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.
    He J; Qiu Z; Fan J; Xie X; Sheng Q; Sui X
    Signal Transduct Target Ther; 2024 Aug; 9(1):209. PubMed ID: 39138145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of cell density and intratumoral heterogeneity in multidrug resistance.
    Lavi O; Greene JM; Levy D; Gottesman MM
    Cancer Res; 2013 Dec; 73(24):7168-75. PubMed ID: 24163380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.